MINNEAPOLIS, MINNESOTA–(Marketwired – May 1, 2017) – DiaMedica Therapeutics Inc. (the “Company“) (TSX VENTURE:DMA)(OTCQB:DMCAF), today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,616,015, entitiled “Formulation of Human Tissue Kallikrein-1 for Parenteral Delivery and Related Methods” for DM199. The patent protects the methods of parenterally administrating DM199 to patients in need where absorption into the circulation via methods such as intravenous (“IV”) or subcutaneous administration improves systemic pharmacokinetics (“PK”), bioavailability, safety, and/or convenience related to IV or other forms of administration. The patent has an expiration date of 2035, which does not include any potential patent term extension.
“We are very excited to have received additional patent protection covering parenteral delivery, including subcutaneous and IV administration and related methods,” said Rick Pauls, President & CEO of DiaMedica Therapeutics. “We believe these methods of delivery could more completely address the needs of patients by offering better options for acute and chronic therapy.”
In a recent clinical trial, a dose of DM199 administered via IV infusion mimicked the anticipated drug profile of IV-administered urinary KLK1 (Kailikang®). This study also identified a dose of DM199 via subcutaneous injection having a superior PK profile that maintains KLK1 levels throughout day. The Company believes this profile could improve the efficacy of DM199.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please vist www.diamedica.com. Follow us on social media – Twitter, LinkedIn.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words “may”, “will”, “anticipate”, “believe”, “estimate”, “expect”, “intend” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica’s filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941
[email protected]
www.diamedica.com
